4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX 263 MG / 100 ML
L-PHENYLALANINE HYDROCHLORIDE : 263 MG / 100 ML L-PROLINE : 178 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 263 MG / 100 ML TRYPTOPHAN : 76 MG / 100 ML L-VALINE : 195 MG / 100 ML L-ISOLEUCINE : 203 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178 MG / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML HISTIDINE : 186 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML DEXTROSE : 5 G / 100 ML GLYCINE : 880 MG / 100 ML L-ALANINE : 880 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML METHIONINE : 246 MG / 100 ML L-TYROSINE : 17 MG / 100 ML L-ARGININE : 440 MG / 100 ML L-LYSINE HYDROCHLORIDE : 246 MG / 100 ML · DIN 02014017 · BAXTER CORPORATION CLINTEC NUTRITION DIVISION
Health Canada status: CANCELLED POST MARKET
What is 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX?
4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX 263 MG / 100 ML contains L-PHENYLALANINE HYDROCHLORIDE : 263 MG / 100 ML L-PROLINE : 178 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 263 MG / 100 ML TRYPTOPHAN : 76 MG / 100 ML L-VALINE : 195 MG / 100 ML L-ISOLEUCINE : 203 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178 MG / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML HISTIDINE : 186 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML DEXTROSE : 5 G / 100 ML GLYCINE : 880 MG / 100 ML L-ALANINE : 880 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML METHIONINE : 246 MG / 100 ML L-TYROSINE : 17 MG / 100 ML L-ARGININE : 440 MG / 100 ML L-LYSINE HYDROCHLORIDE : 246 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02014017, held by BAXTER CORPORATION CLINTEC NUTRITION DIVISION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 02-Aug-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02014017 |
|---|---|
| Brand name | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX |
| Generic / active ingredient | L-PHENYLALANINE HYDROCHLORIDE : 263 MG / 100 ML L-PROLINE : 178 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 263 MG / 100 ML TRYPTOPHAN : 76 MG / 100 ML L-VALINE : 195 MG / 100 ML L-ISOLEUCINE : 203 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178 MG / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML HISTIDINE : 186 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML DEXTROSE : 5 G / 100 ML GLYCINE : 880 MG / 100 ML L-ALANINE : 880 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML METHIONINE : 246 MG / 100 ML L-TYROSINE : 17 MG / 100 ML L-ARGININE : 440 MG / 100 ML L-LYSINE HYDROCHLORIDE : 246 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION CLINTEC NUTRITION DIVISION |
| Strength | 263 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Aug-2007 |
| Original market date | 1995-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013967 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.